Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REMS Must Be Designed With Input From Doctors, Kaiser Tells FDA In Petition

Executive Summary

Kaiser Permanente is pressing FDA to open up the process for creating Risk Evaluation and Mitigation Strategies to a broader audience

You may also be interested in...



FDA Seeks To Write MedGuides Outside REMS Process

FDA is searching for a way out of imposing a REMS when only a medication guide is required

FDA Seeks To Write MedGuides Outside REMS Process

FDA is searching for a way out of imposing a REMS when only a medication guide is required

FDA Seeks To Write MedGuides Outside REMS Process

Agency advice on REMS evolves as FDA gains experience with the program, OSE Director Dal Pan says at DIA.

Related Content

Topics

UsernamePublicRestriction

Register

PS051854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel